Log In
Print
BCIQ
Print
Print this Print this
 

darapladib (SB-480848)

Also known as: Lp-PLA2 inhibitor (480848)

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionSmall molecule inhibitor of vascular inflammation mediator lipoprotein-associated phospholipase A2 (PLA2G7; PAFAH; Lp-PLA2)
Molecular Target Lipoprotein-associated phospholipase A2 (PLA2G7) (PAFAH) (Lp-PLA2)
Mechanism of ActionLipoprotein-associated phopholipase A2 (Lp-PLA2) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3,000.0M

$3,000.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today